Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non-small cell lung cancer

被引:32
作者
Kuo, Shuenn-Wen
Chen, Jin-Shing
Huang, Pei-Ming
Hsu, Hsao-Hsun
Lai, Hong-Shiee
Lee, Jang-Ming [1 ,2 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Surg, Div Thorac Surg, Taipei 10002, Taiwan
[2] Natl Taiwan Univ, Coll Med, Taipei 10002, Taiwan
关键词
VINORELBINE PLUS CISPLATIN; RISK-FACTORS; 7TH EDITION; RECURRENCE; SURVIVAL;
D O I
10.1016/j.jtcvs.2014.04.038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: For stage I non-small cell lung cancer (NSCLC), the only 2 prognostic factors incorporated into the seventh edition of the TNM staging system were tumor size and visceral pleural invasion. However, with this staging system, the prognostic precision of survival has proved elusive, suggesting the need to include additional prognostic factors. To improve prognostic applications and treatment decisions, we investigated clinicopathologic factors affecting progression-free survival in patients with surgically resected stage I NSCLC. Methods: From January 2004 to December 2011, we retrospectively reviewed the clinicopathologic characteristics of 758 consecutive patients with surgically resected stage I NSCLC at the National Taiwan University Hospital. Results: The 5-year progression-free survival rate was 82.3% and 64.0% for those with stage IA (n = 481) and stage IB (n = 277), respectively. Multivariate analysis revealed poor or moderate histologic differentiation and elevated preoperative serum carcinoembryonic antigen were statistically significant risk factors for recurrence in patients with stage IA. Poor or moderate histologic differentiation, elevated preoperative serum carcinoembryonic antigen, lymphovascular invasion, and tumor size > 2 cm were statistically significant risk factors for recurrence in patients with stage I NSCLC. The 5-year progression-free survival rate was 93.0%, 73.8%, and 40.6% for stage I patients with no, 1 or 2, and > 2 risk factors, respectively (P <. 001). Conclusions: In addition to tumor size, we identified 3 other independent risk factors for recurrence in patients with stage I NSCLC. These 3 risk factors warrant consideration as additional predictors in the next version of the TNM staging system.
引用
收藏
页码:1200 / +
页数:11
相关论文
共 21 条
  • [1] Factors predicting poor survival after resection of stage IA non-small cell lung cancer
    Chang, Michael Y.
    Mentzer, Steven J.
    Colson, Yolonda L.
    Linden, Philip A.
    Jaklitsch, Michael T.
    Lipsitz, Stuart R.
    Sugarbaker, David J.
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2007, 134 (04) : 850 - 856
  • [2] Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]):: a randomised controlled trial
    Douillard, Jean-Yves
    Rosell, Rafael
    De Lena, Mario
    Carpagnano, Francesco
    Ramlau, Rodryg
    Gonzales-Larriba, Jose Luis
    Grodzki, Tornasz
    Pereira, Jose Rodrigues
    Le Groumellec, Alain
    Lorusso, Vito
    Clary, Claude
    Torres, Antonio J.
    Dahabreh, Jabrail
    Souquet, Pierre-Jean
    Astudillo, Julio
    Fournel, Pierre
    Artal-Cortes, Angel
    Jassem, Jacek
    Koubkova, Leona
    His, Patricia
    Riggi, Marcella
    Hurteloup, Patrick
    [J]. LANCET ONCOLOGY, 2006, 7 (09) : 719 - 727
  • [3] Edge S., 2010, AJCC Cancer Staging Manua, P253
  • [4] Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
    Grunnet, M.
    Sorensen, J. B.
    [J]. LUNG CANCER, 2012, 76 (02) : 138 - 143
  • [5] Lung cancer
    Hoffman, PC
    Mauer, AM
    Vokes, EE
    [J]. LANCET, 2000, 355 (9202) : 479 - 485
  • [6] PROGNOSTIC FACTORS OBTAINED BY A PATHOLOGICAL EXAMINATION IN COMPLETELY RESECTED NON-SMALL-CELL LUNG-CANCER - AN ANALYSIS IN EACH PATHOLOGICAL STAGE
    ICHINOSE, Y
    YANO, T
    ASOH, H
    YOKOYAMA, H
    YOSHINO, I
    KATSUDA, Y
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 110 (03) : 601 - 605
  • [7] Factors associated with recurrence in patients with curatively resected stage I-II lung cancer
    Koo, Hyeon-Kyoung
    Jin, Sang-Man
    Lee, Chang-Hoon
    Lim, Hyo-Jeong
    Yim, Jae-Joon
    Kim, Young Tae
    Yang, Seok-Chul
    Yoo, Chul-Gyu
    Han, Sung Koo
    Kim, Joo Hyun
    Shim, Young-Soo
    Kim, Young Whan
    [J]. LUNG CANCER, 2011, 73 (02) : 222 - 229
  • [8] Molecular Predictors of Prognosis in Lung Cancer
    Lin, Jules
    Beer, David G.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (02) : 669 - 676
  • [9] Risk Factors for Tumor Recurrence in Patients With Early-Stage (Stage I and II) Non-small Cell Lung Cancer Patient Selection Criteria for Adjuvant Chemotherapy According to the Seventh Edition TNM Classification
    Maeda, Ryo
    Yoshida, Junji
    Ishii, Genichiro
    Hishida, Tomoyuki
    Nishimura, Mitsuyo
    Nagai, Kanji
    [J]. CHEST, 2011, 140 (06) : 1494 - 1502
  • [10] Long-Term Survival and Risk Factors for Recurrence in Stage I Non-Small Cell Lung Cancer Patients With Tumors up to 3 cm in Maximum Dimension
    Maeda, Ryo
    Yoshida, Junji
    ishii, Cenichiro
    Hishida, Tomoyuki
    Aokage, Keiju
    Nishimura, Mitsuyo
    Nishiwaki, Yutaka
    Nagai, Kanji
    [J]. CHEST, 2010, 138 (02) : 357 - 362